Plain-English translation of NCT07451795 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This clinical trial is testing whether SHR-1701, a new medication that helps boost your immune system, works better when combined with targeted radiation therapy for men with advanced prostate cancer. The cancer being studied has spread to other parts of the body and no longer responds to standard hormone treatments. Half the participants will receive radiation plus the medication, while the other half will receive radiation alone, so researchers can compare which approach works better.
When prostate cancer spreads and stops responding to hormone therapy, treatment options become limited. Radiation can destroy cancer in specific spots, and this medication might help your immune system recognize and fight cancer cells more effectively—researchers want to see if combining these two approaches can help patients live longer and feel better.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to one of two groups: one group receives targeted radiation therapy followed by the new medication (given as an intravenous infusion every 3 weeks for at least 2 cycles, then continued alone until your cancer progresses), and the other group receives radiation therapy alone. You will have regular clinic visits for blood tests, imaging scans, and physical exams to monitor how your cancer is responding and whether you are experiencing any side effects. The study involves 66 participants total and will continue until your cancer shows signs of growth or you and your doctor decide to stop.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
China